Avalon Globocare CORP 8-K filings

Avalon GloboCare Corp. received a delisting notice from Nasdaq after failing to regain compliance with the minimum bid price requirement despite a recent reverse stock split.

Avalon GloboCare has appointed Dr. Charles Cavo to its Scientific Advisory Board to support the marketing and business development of KetoAir, a handheld breathalyzer for ketogenic health.

Avalon GloboCare Corp. has executed a 1-for-15 reverse stock split and reduced its authorized shares from 490 million to 100 million, effective October 25, 2024.

Avalon GloboCare has signed a memorandum of understanding with Qi Diagnostics to explore the co-development of a real-time cannabis breathalyzer.

Avalon GloboCare Corp. will implement a 1-for-15 reverse stock split on October 28, 2024, to meet Nasdaq's minimum bid price requirement.

Avalon GloboCare Corp. held its 2024 annual meeting, where stockholders voted on key proposals including the election of directors, ratification of the auditor, and approval of a reverse stock split.

Avalon GloboCare will sponsor the Keto Pa-LOU-za 2024 Conference to showcase and sell their KetoAir breathalyzer device.

Avalon GloboCare's partner, Laboratory Services MSO, is set to launch sales of the FDA-registered GeeWhiz External Condom Catheter in Q3 2024, targeting the growing male urinary incontinence market.

Avalon GloboCare's Laboratory Services MSO has launched a direct-to-consumer DNA test in the U.S. to assess an individual's genetic predisposition to opioid dependence.

Avalon GloboCare has officially launched online sales of its KetoAir breathalyzer in the U.S., featuring AI-powered nutritional recommendations.

Avalon GloboCare Corp. has dismissed Marcum LLP as its independent auditor and appointed M&K CPAS, PLLC, effective July 10, 2024.

Avalon Globocare Corp. has entered into a securities purchase agreement for $2.845 million in convertible notes, along with warrants and common stock issuances.

Avalon GloboCare Corp. has received a notice from Nasdaq for not filing its quarterly report, putting the company at risk of delisting if compliance is not regained.

Avalon GloboCare Corp. has been granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price requirement, now until October 28, 2024.

Avalon Globocare Corp. has entered into mortgage and security agreements with Mast Hill Fund L.P. and Firstfire Global Opportunities Fund, LLC to secure a total of $2.7 million in debt.